Health care stocks were mixed pre-bell Monday as the iShares Biotechnology ETF (IBB) was up 0.2% and the Health Care Select Sector SPDR Fund (XLV) was 0.1% lower recently.
PTC Therapeutics (PTCT) shares advanced by over 17% after the company said it signed an exclusive global license and collaboration agreement for its PTC518 Huntington's disease program with a subsidiary of Novartis (NVS), and will receive a $1 billion upfront payment.
Zai Lab (ZLAB) and NovoCure (NVCR) said their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival. NovoCure shares rose past 45% premarket.
Olema Pharmaceuticals (OLMA) shares were nearly 9% higher after the company said it has launched a clinical trial collaboration and supply agreement with Novartis (NVS) for a frontline metastatic breast cancer treatment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。